Journal article icon

Journal article

A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.

Abstract:

In high-activity rhenium-186 hydroxyethylidene diphosphonate ((186)Re-HEDP) treatment of bone metastatic disease from prostate cancer the dose-limiting factor is haematological toxicity. In this study, we examined the correlation of the injected activity and the whole-body absorbed dose with treatment toxicity and response. Since the best response is likely to be related to the maximum possible injected activity limited by the whole-body absorbed dose, the relationship between pre-therapy bio...

Expand abstract

Actions


Access Document


Publisher copy:
10.1007/s00259-003-1197-y

Authors


Expand authors...
Journal:
European journal of nuclear medicine and molecular imaging
Volume:
30
Issue:
8
Pages:
1114-1124
Publication date:
2003-08-01
DOI:
EISSN:
1619-7089
ISSN:
1619-7070
Source identifiers:
278761

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP